Teva 1Q Revenues: $2.6 billion (+9%) 1Q Earnings: $444 million (-40%) Comments: Generic revenues were $2.6 billion, up 9%. U.S. revenues of $1.4 billion, up 37% mainly from the launch of esomeprazole (a generic of Nexium). European revenues were $680 million, down 17% mainly from the company’s strategy of pursuing sustainable business in the region, with significant decreases in Spain and France, offset by increases in Italy and Germany. ROW revenues were $502 million, down 6%. API sales to t...